Branch retinal vein occlusion (BRVO) is when a blockage forms in the veins branching off the retina, which can disrupt blood flow. Treatment depends on the type of blockage and severity of the damage.

CRVO occurs when blood can no longer travel through the main blood vessel that brings blood to the back of the eye. This can cause swelling, and it may lead to vision loss. The retina is a layer of ...

– RVO is the third indication for Vabysmo, in addition to wet, or neovascular, age-related macular degeneration and diabetic macular edema – – Approval is based on two Phase III studies demonstrating ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved Vabysmo for the treatment of macular edema following retinal vein occlusion. This is the third ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The continued evolution of treatment protocols and ...

CHICAGO -- A novel antibody-biopolymer conjugate (ABC) achieved visual acuity comparable to aflibercept (Eylea) for retinal vein occlusion (RVO) with less frequent dosing, according to a randomized ...

Regeneron (NASDAQ:REGN) announced Tuesday that Eylea HD, the high-dose version of its blockbuster eye care medication Eylea marketed with Bayer (OTCPK:BAYZF), reached the primary goal in a Phase 3 ...

SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), today announced positive topline long-term results from the global Phase III BALATON ...

DelveInsight's, “Retinal Vein Occlusion Pipeline Insight, 2025,” report provides comprehensive insights about 15+ companies and 15+ pipeline drugs in Retinal Vein Occlusion pipeline landscape. It ...

‒ If approved, RVO would be the third indication for Vabysmo in addition to wet age-related macular degeneration (AMD) and diabetic macular edema (DME) – ‒ Vabysmo is currently approved in 60 ...